Time-Dependent Effects of Clinical Interventions on SARS-CoV-2 Immunity in Patients with Lung Cancer

Philip C. Mack,Chih-Yuan Hsu,Ananda M. Rodilla,Jorge E. Gomez,Jazz Cagan,Yuanhui Huang,Sooyun Tavolacci,Rajesh M. Valanparambil,Nicholas Rohs,Rachel Brody,Brittney Nichols,Juan Manuel Carreño,Sheena Bhalla,Christian Rolfo,David E. Gerber,Amy Moore,Jennifer C. King,Rafi Ahmed,John D. Minna,Paul A. Bunn,Adolfo García-Sastre,Florian Krammer,Fred R. Hirsch,Yu Shyr

DOI: https://doi.org/10.3390/vaccines12070713

2024-06-27

Vaccines

Abstract:In patients with lung cancer (LC), understanding factors that impact the dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike antibody (SAb) titers over time is critical, but challenging, due to evolving treatments, infections, vaccinations, and health status. The objective was to develop a time-dependent regression model elucidating individual contributions of factors influencing SAb levels in LC patients using a prospective, longitudinal, multi-institutional cohort study initiated in January 2021. The study evaluated 296 LC patients—median age 69; 55% female; 50% stage IV. Blood samples were collected every three months to measure SAb levels using FDA-approved ELISA. Asymptomatic and unreported infections were documented through measurement of anti-nucleocapsid Ab levels (Meso Scale Discovery). Associations between clinical characteristics and titers were evaluated using a time-dependent linear regression model with a generalized estimating equation (GEE), considering time-independent variables (age, sex, ethnicity, smoking history, histology, and stage) and time-dependent variables (booster vaccinations, SARS-CoV-2 infections, cancer treatment, steroid use, and influenza vaccination). Significant time-dependent effects increasing titer levels were observed for prior SARS-CoV-2 infection (p < 0.001) and vaccination/boosters (p < 0.001). Steroid use (p = 0.043) and chemotherapy (p = 0.033) reduced titer levels. Influenza vaccination was associated with increased SAb levels (p < 0.001), independent of SARS-CoV-2 vaccine boosters. Prior smoking significantly decreased titers in females (p = 0.001). Age showed no association with titers. This GEE-based linear regression model unveiled the nuanced impact of multiple variables on patient anti-spike Ab levels over time. After controlling for the major influences of vaccine and SARS-CoV-2 infections, chemotherapy and steroid use were found to have negatively affected titers. Smoking in females significantly decreased titers. Surprisingly, influenza vaccinations were also significantly associated, likely indirectly, with improved SARS-CoV-2 titers.

immunology,medicine, research & experimental

What problem does this paper attempt to address?

The paper aims to address the issue of changing levels of SARS-CoV-2 antibodies (the virus that causes COVID-19) over time in lung cancer patients. Specifically, the researchers developed a time-dependent regression model to elucidate the various factors affecting the titers of SARS-CoV-2 spike protein antibodies (SAb) in lung cancer patients. These factors include clinical interventions, vaccination, viral infection, cancer treatment, steroid use, and influenza vaccination, among others.

The study employed a prospective, longitudinal, multi-institutional cohort design, starting from January 2021, and evaluated data from 296 lung cancer patients. The study found that previous SARS-CoV-2 infection and vaccination/booster significantly increased antibody levels (p<0.001), while steroid use (p=0.043) and chemotherapy (p=0.033) decreased antibody levels. Surprisingly, influenza vaccination was also associated with an increase in SARS-CoV-2 antibody levels (p<0.001). Additionally, a history of smoking in female patients significantly reduced antibody levels (p=0.001), while age was not significantly associated with antibody levels.

By controlling for the primary effects of vaccination and SARS-CoV-2 infection, the study revealed the negative impact of chemotherapy and steroid use on patients' spike protein antibody levels, as well as the significant indirect positive correlation between influenza vaccination and SARS-CoV-2 antibody levels. This research provides important insights into the complex dynamics of the SARS-CoV-2 immune response in lung cancer patients.